22 results about "Vaccine efficacy" patented technology

An effective treatment method for a broad variety of diseases in both animals and humans is disclosed. The method includes combining one or more vaccines with a treatment compound to enhance vaccine efficacy. The disclosed treatment compound does not act directly on the pathogen, and thus the organisms cannot readily develop resistance to the treatment. When a compound such as, but not limited to, the disclosed compound is used in conjunction with one or more vaccines, a synergistic effect is realized. The suggested compound is derived from a lipopolysaccharide (LPS) of gram negative bacteria. The treatment compound is combined with one or more appropriate vaccines and is administered early in the life of an animal to achieve a synergistic effect compared with the use of the treatment compound or the vaccine alone.

Described herein are novel vaccine compositions and methods for use thereof in inducing an immune response in a subject especially aged subjects. Specifically exemplified are vaccine compositions that include an antigen; a cyclic dinucleotide; soluble tumor necrosis factor (TNF); or a CD64 antibody or antibody fragment. Optionally, the vaccine composition comprises a TNF conjugated with a moDC targeting moiety in addition to or in place of TNF or CD64 antibody or antibody fragment, or both TNF and CD64 antibody or antibody fragment.

The invention discloses an immunogenic composition containing gE virus-like nanoparticles as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises gE virus-like nanoparticles, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the gE virus-like nanoparticles comprise VZV gE, a linker peptide (SGS) and a VZV gI polypeptide containing a Th epitope. The immunogenic composition provided by the invention can be applied to VZV vaccines, and solves the technical problems of weak gE immunogenicity and serious vaccine side reaction in vaccines prepared in the prior art. The immunogenicity of the vaccine is better than that of Xinanliei, the use of an immunopotentiator is reduced, and the clinical side reaction is lower. In addition, the vaccine can also induce an obvious gI specific antibody, which is beneficial for further improving the effectiveness of the vaccine. In short, the immunogenic composition provided by the invention has good clinical application potential.

The invention belongs to the technical field of biology, and particularly relates to a recombinant monoclonal antibody of sheep anti-bluetongue virus VP7 protein. A sheep anti-bluetongue virus antibody library is obtained through a single cell V (D) J sequencing technology, a sheep anti-bluetongue virus VP7 protein recombinant monoclonal antibody is screened and successfully expressed, and it is identified through indirect ELISA and cellular immunofluorescence experiments that the recombinant monoclonal antibody has high affinity with bluetongue virus and can be specifically combined with VP7 protein. The recombinant monoclonal antibody is used as a competitive antibody to establish a competitive ELISA detection method aiming at the bluetongue virus VP7 protein, high specificity of bluetongue antibody detection can be realized, and a basis is provided for mastering the epidemiology of bluetongue virus and evaluating the immune effect of vaccines.

Provided herein are engineered T-celi receptors (TCRs) having nanomoiar affinity for the immuno-dominant pp65 peptide residing between residues 495-503 (NLV) in complex with HLA-A2*02:01. The TCRs may be membrane-hound TCRs, soluble TCRs, chimeric TCRs, or chimeric antigen receptors. Also provided are methods of using the engineered TCRs to treat diseases, monitor disease progression, monitor vaccine efficacy, and detecting NLV / A2 presentation on the surface of cells.

Methods and compositions for monitoring mutation burden, cancer status, vaccine efficacy using cell-free DNA sequencing following enrichment with combination probe panels are disclosed.

Methods and systems for the multiple detection and / or measurement of biomarkers in a sample are provided herein. These methods and systems can be used for rapid disease detection and / or monitoring, monitoring of vaccine efficacy and immune response, monitoring of therapeutic agents, and / or monitoring of the safety and efficacy of treatments.

The invention provides a bivalent vaccine which comprises a rabbit hemorrhagic syndrome virus antigen, a rabbit hepatitis E virus antigen and a microbial freeze-dried slow-release agent, and provides a preparation method which comprises the following steps: culturing the rabbit hepatitis E virus by using passage cells, obtaining the rabbit hepatitis E virus antigen, inoculating the rabbit hemorrhagic syndrome virus, and carrying out freeze-drying on the rabbit hemorrhagic syndrome virus. A rabbit hemorrhagic syndrome virus antigen is obtained, the rabbit hemorrhagic syndrome virus antigen and a rabbit hepatitis E virus antigen are mixed in proportion, a freeze-drying protective agent is supplemented, and the bivalent vaccine is obtained. The invention further provides an application experiment result of the compound, and the compound is used for preventing or treating rabbit hemorrhagic syndrome and rabbit hepatitis E. According to the invention, the two antigens are proportioned properly, so that the prepared vaccine at least achieves the efficacy of preventing and controlling immune epidemic diseases. The bivalent vaccine provided by the invention can prevent two diseases by one injection, reduce immune stimulation, continuously enhance the immune effect of a body, promote the body to generate better immune response, reduce the immune cost, simplify the immune procedure, and is more economical and reliable.

The application belongs to the technical field of biotechnology and relates to the field of veterinary diagnosis, and particularly discloses a liquid-phase blocking ELISA kit for porcine Senecavirus neutralizing antibody, which contains porcine Senecavirus single-domain antibody and matched detection reagents, and the porcine Senecavirus single-domain antibody can also be an antigen-binding fragment of the single-domain antibody, the single-domain antibody is selected from one or more groups in 52 groups, the heavy chain variable region of each group of single-domain antibodies or antigen-binding fragments contains CDR-1, CDR-2 and CDR-3, the amino acid sequences of the heavy chain variable region CDR-1 (VH-CDR-1) of the 52 groups of single-domain antibodies or antigen-binding fragments are respectively shown in SEQ ID NO. 1-SEQ ID NO. 52, the amino acid sequences of the heavy chain variable region CDR-2 (VH-CDR-2) are respectively shown in SEQ ID NO. 53-SEQ ID NO. 104, and the amino acid sequences of the heavy chain variable region CDR-3 (VH-CDR-3) are respectively shown in SEQ ID NO. 105-SEQ ID NO. 156. The kit can quickly detect the SVA neutralizing antibody level in serum, has high sensitivity, good specificity and stable results, and can be better applied to SVA vaccine efficacy evaluation.

This invention discloses a high-affinity mouse anti-eel IgM monoclonal antibody, a hybridoma cell line, and its applications. The mouse anti-eel IgM monoclonal antibody comprises a heavy chain variable region and a light chain variable region. The CDR region of the heavy chain variable region contains three sequences as shown in SEQ ID NO. 1-3, and the CDR region of the light chain variable region contains three sequences as shown in SEQ ID NO. 4-6. The mouse anti-eel IgM monoclonal antibody can be secreted by the hybridoma cell line ArIgMH-33G9D2G7C12, with accession number CCTCC NO: C202545. The mouse anti-eel IgM monoclonal antibody provided by this invention can be used for flow cytometry to identify eel IgM. + This monoclonal antibody, developed for B cells, can be used for the specific detection of secretory IgM in eels via ELISA and Western blot. It exhibits high specificity, sensitivity, and affinity, making it suitable for structural analysis of eel IgM and detection of immune response levels. This lays the foundation for in-depth research on the eel immune system and the establishment of methods for evaluating vaccine efficacy using antibody levels as an indicator.

Methods and compositions are disclosed for monitoring mutational load, cancer status, and vaccine efficacy using cell-free DNA sequencing after enrichment with combinatorial probe panels.

The inventors found that the overexpression of innate immune response and T cell exhaustion pathways is much more pronounced in pigs than in cattle, making pigs less likely than cattle to mount adaptive immune responses and humoral immune responses. This paper presents an innovative strategy to improve the abnormal immune responses in pigs by simultaneously inducing effective cellular and humoral immune responses and applying T cell agonists as new vaccine adjuvants. This result can provide important clues for understanding the differences in immune responses between cattle and pigs, while presenting a method for maximizing immune responses and vaccine efficacy, which are less expressed in pigs than in cattle.

According to the invention, a Chinese forest encephalitis virus inactivated vaccine is adopted to produce a strain'senzheng 'strain gene sequence, a structural protein preM-E gene sequence of the strain is amplified, an HIV-1 lentivirus packaging system is utilized, preM-E is used as a pseudovirus particle envelope protein, green fluorescent protein (EGFP) or luciferase reporter gene (Luciferae) is used as a detection indication signal to prepare the pseudovirus, and a BHK21 cell is used as a target cell; the pseudovirus-BHK21 cell system is used for replacing live virus operation experiments such as vaccine potency evaluation, neutralizing antibody detection (animal method or plaque reduction neutralization test) and the like, the biosafety operation environment is degraded from BSL-3 to BSL-2 by using pseudoviruses, the detection period is shortened, and animal experiments are reduced.

Compositions for determining the efficacy and / or potency of a vaccine preparation are described herein. Splenocytes from immunized animals are isolated and can be frozen. Upon thawing such cells are activated by exposure to a series of dilutions of a vaccine preparation being tested and a series of dilutions of a reference vaccine with known characteristics. Cells secreting immunogen-specific antibody and cells secreting nonspecific antibody are enumerated, as is the amount of immunogen-specific and nonspecific antibody produced. Comparison between the results from the vaccine preparations provides a measure of relative vaccine efficacy and / or potency.

Provided are a vaccine composition for Varicella Zoster virus (VZV) including a glycoprotein E (gE) antigen of VZV and monophosphoryl lipid A (MLA), and a method of using the same. The vaccine composition according to an aspect of the invention may significantly improve a production yield by including the gE antigen having an optimized signal peptide sequence, may enhance immunogenicity by including MLA, and may further enhance the immunogenicity enhanced by MLA by further adding saponin such as QS-21, and may be prepared in a form of CoPoP liposomes so that vaccine antigens may be presented on the surface of the liposomes for better absorption by antigen-presenting cells, and vaccine efficacy may be maximized by inclusion of the vaccine antigens and immune adjuvants in a formulation. Therefore, the vaccine composition may be useful as an alternative to current vaccines in the art for prevention or treatment of VZV infection.

The present application relates to the technical field of biological medicine, and discloses an LDLR intervention adjuvant for promoting antibody production and enhancing vaccine effect and application thereof. The LDLR intervention adjuvant can promote B cell activation and generation of antigen-specific antibodies by down-regulating the expression level of LDLR. The LDLR intervention adjuvant includes, for example, ShRNA or SiRNA for knocking down LDLR gene expression, or PCSK9 functional peptide segments for specifically targeting LDLR protein degradation. The present application proposes a new method for promoting B cell function, i.e. knocking down the expression level of the metabolism-related receptor LDLR, which can effectively promote B cell activation and thus increase the production of specific antibodies.

The application discloses a specific goatpox virus P32 truncated protein and application thereof in vaccine efficacy detection. The amino acid sequence of the protein is shown as SEQ ID NO: 3. The specific truncated form (aa1-aa238) has significantly better soluble expression in E. coli than the full-length and other truncated forms (such as aa1-aa277). A competitive ELISA method for quantitatively detecting the efficacy of bovine nodular skin disease inactivated vaccine is established by taking the specific truncated form as a coating antigen. The method is systematically optimized, and has high sensitivity, strong specificity and good repeatability. Key is that the relative efficacy (RP) value measured by the method is highly correlated with animal challenge protection results, and when the RP value is greater than or equal to 1.0, complete immune protection can be predicted, so that the traditional animal challenge test can be reliably replaced. Compared with the immune challenge method, the detection period is greatly shortened (from 63 days to 2 days), target animals are not used, the detection cost is saved, and the method does not need P3 laboratory conditions and has no biosafety risk.

The invention discloses a non-antigen-dependent antibody rapid enhancement method and application, and relates to the technical field of biology. The method comprises the following steps: applying a non-antigen-dependent antibody rapid enhancer to an organism containing a pre-stored antibody in vivo so as to increase the content of the pre-stored antibody; the non-antigen-dependent antibody rapid enhancer comprises lipid nanoparticles coated with single-stranded oligonucleotide, the nucleotide sequence of the single-stranded oligonucleotide is as shown in SEQ ID NO. 1. According to the method, the level of the pre-stored antibody can be rapidly and remarkably improved in the body with the established immune memory under the condition that the exogenous antigen is completely not required to be stimulated again. The limitation that an existing antibody enhancement strategy must depend on antigens is broken through, and a brand-new technical tool and solution with wide application prospects are provided for quick awakening of vaccine efficacy, emergency enhancement of immune defense and controllable adjustment of in-vivo antibody level in antibody preparation.

The invention relates to a HPV vaccine composition and a dengue vaccine composition for use in a method of preventing an HPV-associated disease and dengue disease in a subject or in a subject population, the method comprising concomitantly administering the HPV vaccine composition and the dengue vaccine composition, wherein the dengue vaccine composition is a tetravalent dengue composition comprising live, attenuated DENV-1, DENV-2, DENV-3 and DENV-4 strains and wherein the method provides combined vaccine efficacy against all four serotypes of the dengue virus and non-inferiority of the immune respone to the HPV vaccine composition compared to a mono-administratrion of the HPV vaccine composition.

Provided are compounds of formula (Ia), (Ib) and (IIa), and pharmaceutically acceptable salts thereof. Additionally provided are compositions and pharmaceutical compositions comprising the compounds, therapeutic methods using same for modulating (e.g., inhibiting) CREB binding protein (CBP) / β-catenin mediated signaling in treating a condition, disease or disorder (e.g., fibrosis, cancer, neurological conditions, metabolic disorders (e.g., diabetes, etc.), and skin conditions (dermatitis, psoriasis, scarring, alopecia, etc.) mediated by aberrant CBP / β-catenin signaling, and cosmetic methods for treating skin conditions (e.g., aging, etc.). Additionally, provided are methods for enhancing vaccine efficacy using the compounds and compositions. Further provided are methods for efficiently synthesizing a clinical grade drug, comprising use, in a penultimate, or last reaction step under GMP conditions, of an intermediate 2-propynyl-compound to form a clinical grade isoxazole derivative (e.g., via 3+2 cycloaddition).

Described herein are novel vaccine compositions and methods for use thereof in inducing an immune response in a subject especially aged subjects. Specifically exemplified are vaccine compositions that include an antigen; a cyclic dinucleotide; soluble tumor necrosis factor (TNF); or a CD64 antibody or antibody fragment. Optionally, the vaccine composition comprises a TNF conjugated with a moDC targeting moiety in addition to or in place of TNF or CD64 antibody or antibody fragment, or both TNF and CD64 antibody or antibody fragment.

Improved vaccine compositions and methods are provided, which incorporate the use of lipid nanoparticles which maintain or improve vaccine efficacy while reducing vaccine toxicity and / or side effects.